SCHEMBL19203450

SCHEMBL19203450

C[C@@H](CO)N(C)Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 2/20 0.69
ADRA2C P18825 2/20 0.69
ADRA1A P35348 2/20 0.69
OPRK1 P41145 2/20 0.69
SLC6A2 P23975 1/20 0.69
HTR2A P28223 1/20 0.69
SLC6A4 P31645 1/20 0.69
SLC6A3 Q01959 1/20 0.69
KCNH2 Q12809 1/20 0.69
TSHR P16473 3/20 0.50
ALDH1A1 P00352 1/20 0.50
TRPA1 O75762 1/20 0.47
AOC3 Q16853 1/20 0.47
HPGD P15428 1/20 0.46
SIGMAR1 Q99720 3/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474512 0.82 ADRA2B (0.50) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL15003030 0.82 ADRA2B (0.71) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL1834931 0.82 TSHR (0.51) ADRA2BADRA2CADRA1AOPRK1SLC6A2
Benzphetamine SCHEMBL678807 0.82 ADRA2B (1.00) ADRA2BADRA2CADRA1AOPRK1SLC6A2
Benzphetamine SCHEMBL49120 0.82 ADRA2B (1.00) ADRA2BADRA2CADRA1AOPRK1SLC6A2
Benzphetamine SCHEMBL19285634 0.82 ADRA2B (1.00) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL10773369 0.82 ADRA2B (0.50) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL6054336 0.82 TSHR (0.51) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL1834929 0.82 TSHR (0.51) ADRA2BADRA2CADRA1AOPRK1SLC6A2
SCHEMBL17559714 0.81 ADRA2B (0.55) ADRA2BADRA2CADRA1AOPRK1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085060-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LTD (GB) 2026-03-26 US disclosed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 US disclosed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 US disclosed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 US disclosed
US-20210395227-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2021-12-23 US disclosed
US-20210395227-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2021-12-23 US disclosed
US-11130746-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2021-09-28 US disclosed
US-20200255404-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2020-08-13 US disclosed
US-10696654-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2020-06-30 US disclosed
US-10696654-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2020-06-30 US disclosed
EP-3408265-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2020-05-13 EP disclosed
EP-3408265-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2020-05-13 EP disclosed
US-20190040041-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2019-02-07 US disclosed
US-20190040041-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2019-02-07 US disclosed
WO-2017158151-A1 PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE SAVIRA PHARMACEUTICALS GMBH (AT) 2017-09-21 WO disclosed
WO-2017129829-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2017-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696654-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-11753398-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-20190040041-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-11130746-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-20200255404-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-20210395227-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ADRA2B 200/4885ADRA2C 148/4885ADRA1A 158/4885
US-20260085060-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ADRA2B 501/4885ADRA2C 1520/4885ADRA1A 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.